Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.

European journal of haematology - 1 Feb 2021

Deshpande Shayu, Tytarenko Ruslana G, Wang Yan, Boyle Eileen M, Ashby Cody, Schinke Carolina D, Thanendrarajan Sharmilan, Zangari Maurizio, Zhan Fenghuang, Davies Faith E, Morgan Gareth J, van Rhee Frits, Walker Brian A

Abstract excerpt

Circulating cell-free DNA (cfDNA) has the potential to capture spatial genetic heterogeneity in myeloma (MM) patients. We assessed whether cfDNA levels vary according to risk status defined by the 70 gene expression profile (GEP70). cfDNA levels in 77 patients were significantly higher in the GEP70 high-risk (HR) group compared to the low-risk (LR) group and correlated weakly with clinical markers including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Computational Biology

Share to Liquid Biopsy

Share to Multiple Myeloma

Share to ras Proteins

Share to Tumor Burden

Source

Identifiers

PMID: 33107092
DOI: 10.1111/ejh.13541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.PMID 33107092Read ↗

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosisSemantic proximity Read ↗

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.Semantic proximity Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cellsSemantic proximity Read ↗

Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNASemantic proximity Read ↗

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Semantic proximity Read ↗

Tracking myeloma tumor DNA in peripheral blood.Semantic proximity Read ↗

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaSemantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor DiseasesSemantic proximity Read ↗

Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.Semantic proximity Read ↗

Analysis of Circulating Tumor DNA.Semantic proximity Read ↗

The clinical value of circulating cell free DNA in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.